Insider buying last 90 days
No open-market insider purchases were filed for IMVT in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every IMVT insider filing, plotted on the chart in Gekko.Open IMVT in Gekko
NASDAQ: IMVT
Immunovant (IMVT) Stock Analysis & Forecast
Sep 28 close
$33.49+0.19 (+0.6%)
Gekko Brief
AI summaryImmunovant fell this week after its lead drug candidate, IMVT-1402, failed to meet its primary endpoint in a proof-of-concept study for cutaneous lupus erythematosus, prompting the company to discontinue that program despite what it described as positive trends and a favorable safety profile. The stock dropped roughly 7% following the announcement, and several law firms, including Levi & Korsinsky, subsequently disclosed investigations into potential securities law violations tied to the disclosure. Separately, commentary following the setback noted that five other ongoing IMVT-1402 programs across autoimmune diseases remain active, alongside the company's cash reserves.
The shares close at $33.49, below both the 50-day average of $39.64 and above the 200-day average of $31.57, reflecting a mixed trend after the one-month return of -23.6% and three-month return of -13%, set against a six-month gain of 39.7% and a one-year gain of 113.7%. The GekkoIndex reads 75.8, placing the stock in the Buying zone, while price sits 13.3% below the Gekko Fair Value of $38.64.
The next earnings report is scheduled for 9 November 2026, before the open, 41 days out and beyond a typical 20-trading-day holding window; the prior report on 6 August showed an EPS beat with a 1.7% reaction. No insider, Congress, or unusual options activity appears in the recent windows, though one billionaire holder is on record. Seasonally, the next 20 trading days have averaged a 22.1% move over 5 years, rising in 3 of them, alongside a typical 20-day move of 9.6%.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Immunovant price vs fair value
Close $33.49200-day averageGekko Fair Value $38.64
Immunovant quick facts
- Market cap
- $6.91B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$2.81
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 0.81
- Volume
- 1.23M avg 1.51M
- 1-year return
- +113.7%
- Typical daily move
- ±4.2%
- Typical 20-day move
- ±9.6%
- 50-day average
- $39.64
- 200-day average
- $31.57
- Next earnings
- Nov 9 before open
- Shares outstanding
- 206.6M
Immunovant swing-trade checklist
Immunovant scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
- Trendmixed
Averages disagree
Close $33.49 sits between the 50-day ($39.64) and 200-day ($31.57) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
75.8, Buying
Reading 75.8 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
13.3% below
Price is 13.3% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 41 days
Next report Nov 9, 2026, 41 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+22.1% on average
From this point in the calendar, the next 20 trading days averaged +22.1% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Immunovant stock chart and price history
Immunovant closed at $33.49 on Sep 28, 2026, +113.7% over the past year, inside a 52-week range of $15.56 to $45.42.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −23.6%
- 3 months
- −13.0%
- 6 months
- +39.7%
- 1 year
- +113.7%
The full IMVT chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open IMVT in Gekko
Follow Immunovant through every session
Put IMVT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track IMVT in GekkoFree for 7 days. No credit card required.
About Immunovant
Immunovant develops monoclonal antibody treatments aimed at autoimmune diseases and remains in the clinical testing stage of drug development. Its lead candidate, batoclimab, is a fully human antibody designed to block the neonatal fragment crystallizable receptor, known as FcRn, which plays a role in a number of autoimmune conditions. The company is best recognized for this program, which spans several disease areas rather than a single condition.
Batoclimab is being studied in Phase IIa trials for myasthenia gravis and thyroid eye disease, and has entered Phase II testing for warm autoimmune hemolytic anemia. Immunovant operates as a subsidiary of Roivant Sciences Ltd, situating its research within that broader corporate structure rather than as a fully independent entity.
The company was founded in 2018 and is headquartered in New York, New York. Its shares are listed on the NASDAQ under the ticker IMVT.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- immunovant.com
Immunovant GekkoIndex: the smart money zone
Immunovant’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 75.8, in the Buying zone, up 8.3 points over five sessions.
75.8Buying
Up 8.3 points over five sessions, from the Accumulation zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 57 | +0.1% | −1.6% | ||
| Accumulation | 236 | −0.8% | −1.9% | ||
| Neutral | 350 | +1.0% | +3.3% | ||
| Distribution | 28 | −2.5% | −4.0% | ||
| Selling | 1 | Too few readings yet | |||
Average IMVT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.2% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the IMVT price, zone by zone.Track IMVT in Gekko
Is Immunovant stock overvalued? Gekko Fair Value
Immunovant trades 13.3% below Gekko Fair Value of $38.64, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Immunovant shares are worth, recalculated every trading day.
$38.64
Gekko Fair Value, Sep 29, 2026
13.3% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open IMVT in Gekko
Immunovant insider and Congress trading
No open-market insider purchases were filed for Immunovant, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in IMVT were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for IMVT, plotted on the chart in Gekko.Open IMVT in Gekko
Hedge funds and billionaires quarter ended Mar 31
1of the funds Gekko tracks holds IMVT.
0added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Immunovant earnings: next date and track record
Immunovant reports on Nov 9, 2026, before the open (41 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 9, 2026
Expected before the open, 41 days away
- EPS estimate
- −$0.73
- Revenue estimate
- $7.10M
3 of 8reports beat the EPS estimate
±8.3%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- Roivant's Q1 2026 earnings call described a quiet quarter operationally but with meaningful programmatic progress and upcoming catalysts. Management highlighted a pending brexpiprazole launch expected by the end of September (PDUFA this quarter), Phase III enrollment started for cutaneous sarcoidosis, continued enrollment for LPP and other brexpiprazole indications, initial settlement payment from Moderna and ongoing international proceedings against Pfizer/BioNTech, and multiple program readouts and regulatory interactions expected in the second half of the year. Management emphasized execution on multiple programs (brepocitinib in dermatomyositis and NIU, mosely/Mosley for PH-ILD, 1402 for difficult-to-treat RA and Graves disease, 402 for MG/CIDP, CLE proof-of-concept), expressed confidence in market opportunity and physician receptivity, and flagged key programmatic risks such as placebo variability in immunology trials and translational risk from PAH to PH-ILD. The tone was measured and optimistic: management repeatedly emphasized progress, patient need, and preparedness for potential launches, while acknowledging uncertainties (placebo response, trial translation, reimbursement dynamics).
- Guidance
- Brexpiprazole expected to launch by the end of September (PDUFA this quarter). Management plans to provide more launch metrics and cadence around approvals as events occur; they did not provide formal quantitative financial guidance for the quarter. They expect multiple program readouts and regulatory interactions in the second half of 2026 and indicated intent to file sNDAs/registrations promptly if pivotal data are positive.
- Risks flagged
- Placebo response variability in immunology trials (could impact Phase III success); translational risk of inhaled vasodilators from PAH to PH-ILD (uncertainty whether PVR reductions will translate); JAK class safety concerns and black box warnings (physician reception and label expectations); reimbursement and formulary timing risks impacting early launch uptake; geographic and baseline variability across Phase III trials (could affect outcomes); regulatory timing and requirement uncertainty (may affect filing cadence).
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.75 est −$0.66 | $7.10M est $7.10M | +1.7% |
| May 20, 2026 | −$0.67 est −$0.63 | — | +29.8% |
| Feb 6, 2026 | −$0.54 est −$0.69 | — est $6.00M | +14.3% |
| Nov 10, 2025 | −$0.73 est −$0.72 | — | −2.0% |
| Aug 11, 2025 | −$0.60 est −$0.69 | — | −1.6% |
| May 29, 2025 | −$0.64 est −$0.71 | — | +5.3% |
| Feb 6, 2025 | −$0.76 est −$0.75 | — | −9.3% |
| Nov 7, 2024 | −$0.74 est −$0.61 | — | −2.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Immunovant stock forecast and analyst price targets
Analysts’ average 12-month price target for Immunovant is $48.88, +46.0% from the last close, from 11 firms rating the stock in the last 90 days.
$48.88consensus 12-month target, +46.0% from the last close
Now $33.49Avg $48.88
Low $37High $66
Each firm’s latest rating in the last 90 days: 11 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 26 | LifeSci Capital | $53 | +58.3% |
| Sep 25 | Bernstein | $37 | +10.5% |
| Sep 24 | Truist Financial | — | — |
| Sep 23 | H.C. Wainwright | $41 | +22.4% |
| Sep 23 | LifeSci Capital | $53 | +58.3% |
−1.6%average 20-day move after past Buying readings
+22.1%average move over the next 20 trading days in the last 5 years
±4.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Immunovant seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Immunovant averaged +22.1% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +18.0% | 4 of 5 |
| Next 10 trading days | +18.7% | 4 of 5 |
| Next 15 trading days | +18.3% | 3 of 5 |
| Next 20 trading days | +22.1% | 3 of 5 |
| Next 30 trading days | +34.3% | 3 of 5 |
For scale, IMVT’s typical 20-trading-day move in either direction is about 9.6%.
Immunovant market cap and key statistics
Immunovant’s market cap is $6.91B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $6.91B
- EPS, TTM
- −$2.81
- Gekko Fair Value
- $38.64
Trading
- Volume
- 1.23M
- Avg volume, 20 days
- 1.51M
- 52-week high
- $45.42
- 52-week low
- $15.56
- Shares outstanding
- 206.6M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -80.1%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.81
- Typical daily move
- ±4.2%
- Typical 20-day move
- ±9.6%
Immunovant stock news this week
Coverage of Immunovant this week reads negative: 1 positive, 3 neutral and 6 negative headlines.
- Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull CaseInsider Monkey, Sep 27
- IMVT Investor Alert: Levi & Korsinsky Investigates Immunovant, Inc. (IMVT) For Potential Securities FraudACCESS Newswire, Sep 26
- Immunovant CLO Christopher Van Tuyl Executes Mandatory Sale of 2,846 Shares for Tax WithholdingKalkine Media, Sep 26
- Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)PR Newswire, Sep 25
- IMVT SHAREHOLDER INVESTIGATION: Levi & Korsinsky Investigates Immunovant, Inc. For Possible Securities Law ViolationsACCESS Newswire, Sep 24
- IMVT Ends Cutaneous Lupus Erythematosus Program, Stock DownZacks Investment Research, Sep 24
Immunovant peers
Immunovant’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 24.4% below |
| GILDGilead Sciences | Neutral | 6.9% above |
| MRNAModerna | Neutral | 73.2% above |
| NTRANatera | Distribution | 25.1% above |
| IQVIQVIA | Neutral | 14.2% above |
| UTHRUnited Therapeutics | Accumulation | 23.6% below |
A peer links to its own page where one exists.
Immunovant stock FAQ
What is Immunovant’s market cap?
Immunovant’s market cap is $6.91B at the Sep 28, 2026 close of $33.49, with 206.6M shares outstanding.
What is the Immunovant stock forecast?
The consensus analyst 12-month price target for Immunovant is $48.88, +46.0% from the last close. Of the 11 firms that rated the stock in the last 90 days, 8 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Immunovant stock overvalued or undervalued?
On Gekko’s estimate Immunovant is undervalued: the Sep 28, 2026 close of $33.49 is 13.3% below Gekko Fair Value of $38.64. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Immunovant report earnings next?
Immunovant is expected to report on Nov 9, 2026, before the market opens (41 days away). Analysts expect earnings of −$0.73 per share on revenue of $7.10M. Immunovant beat the earnings estimate in 3 of its last 8 reports, moving 8.3% on average across the report.
What is Immunovant’s 52-week high and low?
Immunovant’s 52-week high is $45.42 and its 52-week low is $15.56; it closed at $33.49 on Sep 28, 2026, +113.7% over the past year. Over the last five years the shares peaked at $45.58 on Jan 9, 2024.
Is Immunovant stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Immunovant the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.